ImmuPharma plc (LON:IMM – Get Free Report) shares rose 9.3% on Saturday . The stock traded as high as GBX 4.50 ($0.06) and last traded at GBX 3.94 ($0.05). Approximately 31,560,066 shares were traded during mid-day trading, an increase of 60% from the average daily volume of 19,683,289 shares. The stock had previously closed at GBX 3.60 ($0.04).
ImmuPharma Price Performance
The company has a market cap of £16.39 million, a price-to-earnings ratio of -393.60 and a beta of 1.53. The stock has a 50-day moving average price of GBX 1.75 and a 200 day moving average price of GBX 1.73.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Further Reading
- Five stocks we like better than ImmuPharma
- What is the Shanghai Stock Exchange Composite Index?
- Bloom Energy: Powering the Future With Decentralized Energy
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Dividend Powerhouses: Blue-Chip Stocks Built for the Long Haul
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Why Traders Are Buying the Dip on Johnson & Johnson Stock
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
